Analysis
Suki raised a $90 million Series E, adding new investors Healthier Capital, Crosslink Capital and Hercules Capital to scale its AI agents for health systems, the company said in a release carried on FinancialContent on October 13.
Existing backers Venrock, Flare Capital Partners, Hedosophia, Philips Ventures and Zoom Ventures also participated. Healthier Capital partner Aman Mahajan is joining Suki's board as part of the round, and the company says the money will go toward AI development, its partner ecosystem and its commercial organization -- not merely more ambient transcription, but expansion into tasks after the patient visit, like referrals and scheduling.
From scribe to agent
Suki's framing has shifted deliberately: founder and CEO Punit Soni said "clinical documentation was never the destination -- it was the entry point," positioning the company's original ambient-scribe product as a wedge into broader agentic clinical workflows. The company says patient encounters supported by its AI grew more than 190% year-over-year in 2026, and that revenue from its technology-partner business has grown more than tenfold over the past two years.
Suki was founded in 2017 and originally marketed itself as a voice assistant for doctors. Bloomberg reported that a 2021 Series C valued the company at $400 million at the time -- the last disclosed valuation benchmark, since Tuesday's release does not state a new one. The round itself reflects how far ambient AI has moved from novelty voice tools toward infrastructure health systems now budget for annually, a shift from novelty tool to recurring line item.
Suki now serves more than 450 healthcare organizations and over 30 technology partners, competing in an AI-scribe market that includes Abridge, Microsoft-owned Nuance, and Ambience Healthcare, which closed its own $234 million Series C according to a Fenwick & West summary of that deal. Suki's $90 million is smaller than Ambience's round, a gap that suggests investors are still differentiating between ambient-AI vendors on traction and partnerships rather than simply funding the category broadly.
The release does not disclose a post-money valuation, a detail that will matter once Suki or a competitor needs to raise again in a market where AI-scribe valuations have moved quickly. Watch whether Suki's shift into referrals and scheduling actually reduces health-system administrative costs enough to justify premium pricing, or whether it simply adds feature sprawl to a crowded point solution.